Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis

Ann Taber,Emil Christensen,Philippe Lamy,Iver Nordentoft,Frederik Prip,Sia Viborg Lindskrog,Karin Birkenkamp-Demtröder,Trine Line Hauge Okholm,Michael Knudsen,Jakob Skou Pedersen,Torben Steiniche,Mads Agerbæk,Jørgen Bjerggaard Jensen,Lars Dyrskjøt

DOI: https://doi.org/10.1038/s41467-020-18640-0

IF: 16.6

2020-09-25

Nature Communications

Abstract:Abstract Overtreatment with cisplatin-based chemotherapy is a major issue in the management of muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for predicting response have been implemented in the clinic. Here we perform a comprehensive multi-omics analysis (genomics, transcriptomics, epigenomics and proteomics) of 300 MIBC patients treated with chemotherapy (neoadjuvant or first-line) to identify molecular changes associated with treatment response. DNA-based associations with response converge on genomic instability driven by a high number of chromosomal alterations, indels, signature 5 mutations and/or BRCA2 mutations. Expression data identifies the basal/squamous gene expression subtype to be associated with poor response. Immune cell infiltration and high PD-1 protein expression are associated with treatment response. Through integration of genomic and transcriptomic data, we demonstrate patient stratification to groups of low and high likelihood of cisplatin-based response. This could pave the way for future patient selection following validation in prospective clinical trials.

multidisciplinary sciences